Page 24 - 80_02

Development
of
anti-­-Leishmania
vaccines…

protective
immunity
against
visceral
leishmaniasis
in
mice.
Vaccine
25,
2168-­-2172

(2007).

86
Dondji,
B.;
Perez-­-Jimenez,
E.;
Goldsmith-­-Pestana,
K.;
Esteban,
M.;
McMahon-­-Pratt,
D.

Heterologous
prime-­-boost
vaccination
with
the
LACK
antigen
protects
against
murine

visceral
leishmaniasis.
Infection
and
Immunity
73,
5286-­-5289
(2005).

87
Gonzalo,
R.
M.;
Rodriguez,
J.
R.;
Rodriguez,
D.;
Gonzalez-­-Aseguinolaza,
G.;
Larraga,
V.;

Esteban,
M.
Protective
immune
response
against
cutaneous
leishmaniasis
by

prime/booster
immunization
regimens
with
vaccinia
virus
recombinants
expressing

Leishmania
infantum
p36/LACK
and
IL-­-12
in
combination
with
purified
p36.
Microbes
and

Infection
3,
701-­-711
(2001).

88
Gonzalo,
R.
M.;
del
Real,
G.;
Rodriguez,
J.
R.;
Rodriguez,
D.;
Heljasvaara,
R.;
Lucas,
P.;

Larraga,
V.;
Esteban,
M.
A
heterologous
prime-­-boost
regime
using
DNA
and
recombinant

vaccinia
virus
expressing
the
Leishmania
infantum
P36/LACK
antigen
protects
BALB/c

mice
from
cutaneous
leishmaniasis.
Vaccine
20,
1226-­-1231
(2002).

89
Ramos,
I.;
Alonso,
A.;
Marcen,
J.
M.;
Peris,
A.;
Castillo,
J.
A.;
Colmenares,
M.;
Larraga,
V.

Heterologous
prime-­-boost
vaccination
with
a
non-­-replicative
vaccinia
recombinant
vector

expressing
LACK
confers
protection
against
canine
visceral
leishmaniasis
with
a

predominant
Th1-­-specific
immune
response.
Vaccine
26,
333-­-344
(2008).

90
Dondji,
B.;
Deak,
E.;
Goldsmith-­-Pestana,
K.;
Perez-­-Jimenez,
E.;
Esteban,
M.;
Miyake,
S.;

Yamamura,
T.;
McMahon-­-Pratt,
D.
Intradermal
NKT
cell
activation
during
DNA
priming
in

heterologous
prime-­-boost
vaccination
enhances
T
cell
responses
and
protection
against

Leishmania.
European
Journal
of
Immunology
38,
706-­-719
(2008).

91
Ramos,
I.;
Alonso,
A.;
Peris,
A.;
Marcen,
J.
M.;
Abengozar,
M.
A.;
Alcolea,
P.
J.;
Castillo,
J.
A.;

Larraga,
V.
Antibiotic
resistance
free
plasmid
DNA
expressing
LACK
protein
leads
towards

a
protective
Th1
response
against
Leishmania
infantum
infection.
Vaccine
27,
6695-­-6703

(2009).

92
Sanchez-­-Sampedro,
L.;
Gomez,
C.
E.,
Mejias-­-Perez,
E.;
Sorzano,
C.
O.;
Esteban,
M.
High

quality
long-­-term
CD4+
and
CD8+
effector
memory
populations
stimulated
by
DNA-­-
LACK/MVA-­-LACK
regimen
in
Leishmania
major
BALB/c
model
of
infection.
PLoS
One.
7,

e38859
(2012).

93
Perez-­-Jimenez,
E.;
Kochan,
G.;
Gherardi,
M.
M.;
Esteban,
M.
MVA-­-LACK
as
a
safe
and

efficient
vector
for
vaccination
against
leishmaniasis.
Microbes
and
Infection
8,
810-­-822

(2006).

94
Tapia,
E.;
Perez-­-Jimenez,
E.;
Lopez-­-Fuertes,
L.;
Gonzalo,
R.;
Gherardi,
M.
M.;
Esteban,
M.
The

combination
of
DNA
vectors
expressing
IL-­-12
+
IL-­-18
elicits
high
protective
immune

response
against
cutaneous
leishmaniasis
after
priming
with
DNA-­-p36/LACK
and
the

cytokines,
followed
by
a
booster
with
a
vaccinia
virus
recombinant
expressing
p36/LACK.

Microbes
and
Infection
5,
73-­-84
(2003).

95
Ramiro,
M.
J.;
Zarate,
J.
J.;
Hanke,
T.;
Rodriguez,
D.;
Rodriguez,
J.
R.;
Esteban,
M.;
Lucientes,

J.;
Castillo,
J.
A.;
Larraga,
V.
Protection
in
dogs
against
visceral
leishmaniasis
caused
by

Leishmania
infantum
is
achieved
by
immunization
with
a
heterologous
prime-­-boost

regime
using
DNA
and
vaccinia
recombinant
vectors
expressing
LACK.
Vaccine
21,
2474-­-
2484
(2003).

96
Dominguez-­-Bernal,
G.;
Horcajo,
P.;
Orden,
J.
A.;
De
La
Fuente,
R.;
Herrero-­-Gil,
A.;
Ordonez-­-
Gutierrez,
L.;
Carrion,
J.
Mitigating
an
undesirable
immune
response
of
inherent

susceptibility
to
cutaneous
leishmaniosis
in
a
mouse
model:
the
role
of
the
pathoantigenic

HISA70
DNA
vaccine.
Veterinary
Research
43,
59
(2012).

97
Parody,
N.;
Soto,
M.;
Requena,
J.
M.;
Alonso,
C.
Adjuvant
guided
polarization
of
the
immune

humoral
response
against
a
protective
multicomponent
antigenic
protein
(Q)
from

Leishmania
infantum.
A
CpG
+
Q
mix
protects
Balb/c
mice
from
infection.
Parasite

Immunology
26,
283-­-293
(2004).

98
Molano,
I.;
Alonso,
M.
G.;
Miron,
C.;
Redondo,
E.;
Requena,
J.
M.;
Soto,
M.;
Nieto,
C.
G.;

Alonso,
C.
A
Leishmania
infantum
multi-­-component
antigenic
protein
mixed
with
live
BCG

confers
protection
to
dogs
experimentally
infected
with
L.
infantum.
Veterinary

Immunology
Immunopathology
92,
1-­-13
(2003).

99
Carcelen,
J.;
Iniesta,
V.;
Fernandez-­-Cotrina,
J.;
Serrano,
F.;
Parejo,
J.
C.;
Corraliza,
I.;

Gallardo-­-Soler,
A.;
Marañon,
F.;
Soto,
M.;
Alonso,
C.;
Gomez-­-Nieto,
C.
The
chimerical
multi-­-
component
Q
protein
from
Leishmania
in
the
absence
of
adjuvant
protects
dogs
against
an

experimental
Leishmania
infantum
infection.
Vaccine.
27,
5964-­-5973
(2009).

263